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Abstract  
Chronic hepatitis B virus (HBV) infection remains a significant global health problem. 
Evidence-based guidelines are needed to help providers determine when treatment should be 
initiated, which medication is most appropriate, and when treatment can safely be stopped. The 
American Association for the Study of Liver Diseases (AASLD) HBV guideline methodology 
and writing committees developed a protocol a priori for this systematic review. We searched 
multiple databases for randomized controlled trials (RCTs) and controlled observational studies 
that enrolled adults ≥18 years old diagnosed with chronic HBV infection who received antiviral 
therapy. Data extraction was done by pairs of independent reviewers. We included 73 studies; of 
which 59 (15 RCTs and 44 observational studies) reported clinical outcomes. Moderate quality 
evidence supported the effectiveness of antiviral therapy in patients with immune active chronic 
HBV infection in reducing the risk of cirrhosis, decompensated liver disease, and hepatocellular 
carcinoma. In immune-tolerant patients, moderate quality evidence supports improved 
intermediate outcomes with antiviral therapy. Only very low quality evidence informed the 
questions about discontinuing vs. continuing antiviral therapy in hepatitis B e antigen (HBeAg) 
positive patients who seroconverted from HBeAg to HBe antibody and about the safety of 
entecavir vs. tenofovir. Non-comparative and indirect evidence was available for questions about 
stopping vs. continuing antiviral therapy in HBeAg negative patients; monotherapy vs. adding a 
second agent in patients with persistent viremia during treatment; and the effectiveness of 
antivirals in compensated cirrhosis with low level viremia. Conclusion: Most of the current 
literature focuses on the immune active phases of chronic HBV infection. Decision-making in 
other commonly encountered and challenging clinical settings depends on indirect evidence. 
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Introduction: 
Chronic hepatitis B virus (HBV) infection remains a significant global health problem. Despite 
the availability of HBV vaccines for three decades, the global prevalence of chronic HBV 
infection has only declined slightly, from 4.2% in 1990 to 3.7% in 2005 (1). Worldwide, 
however, the absolute number of persons chronically infected has increased from 223 million in 
1990 to 240 million in 2005. In the United States (US), based on 1999-2006 data from the 
National Health and Nutrition Examination Surveys (NHANES), the prevalence of chronic HBV 
infection was estimated to be 0.27% (2).  However, NHANES under-sampled high prevalence 
groups, so when accounting for immigration from endemic countries, as many as 2.2 million US 
residents (instead of 730,000) may have chronic HBV infection (3).  
The natural course of chronic HBV infection consists of four characteristic phases: immune 
tolerant, hepatitis B e antigen (HBeAg)-positive immune active, inactive, and HBeAg-negative 
immune active phases (4).  The immune tolerant phase is characterized by the presence of 
HBeAg, normal alanine aminotransferase (ALT) levels and high levels of HBV DNA usually 
well over 20,000 IU/ml.  The immune active phases, also called HBeAg-positive or HBeAg-
negative chronic hepatitis, are characterized by intermittently or persistently elevated ALT with 
active hepatic inflammation and HBV DNA generally above 2,000 IU/ml. The inactive phase is 
characterized by absence of HBeAg and presence of hepatitis B e antibody (anti-HBe), normal 
ALT in the absence of other concomitant liver diseases, and undetectable or low levels of HBV 
DNA generally below 2,000 IU/ml. Although not all patients go through each phase and immune 
responses to HBV during each phase have not been fully characterized, this classification schema 
provides a useful framework when developing a management approach for chronic HBV 
infection.  
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Currently, seven medications are approved for treatment of chronic HBV infection: two 
formulations of interferon (IFN) - standard and pegylated (Peg IFN), and five nucleos(t)ide 
analogues: lamivudine, telbivudine, entecavir, adefovir and tenofovir.  These medications 
suppress HBV replication and ameliorate hepatic inflammation but do not eradicate HBV. While 
IFN is given for a finite duration, nucleos(t)ide analogues are administered for many years and 
often for life. Long durations of treatment are associated with risks of adverse reactions, drug 
resistance, non-adherence, and increased cost. Therefore, there is a need to have evidence-based 
guidelines to help providers determine when treatment should be initiated, which medication is 
most appropriate, and when treatment can safely be stopped.   
Methods: 
The American Association for the Study of Liver Diseases (AASLD) HBV guideline 
methodology and writing committees developed a protocol a priori for this systematic review. 
The reporting of this review follows the standards set in the Preferred Reporting Items for 
Systematic Reviews and Meta-analysis (PRISMA) statement (5). The committee identified and 
developed a protocol for 7 key Population Intervention Comparison Outcome (PICO) questions 
(Supplemental Table 1). The outcomes of interest were clinical outcomes (cirrhosis, liver 
decompensation, hepatocellular carcinoma [HCC] and all-cause mortality); however, when such 
outcome data were unavailable, surrogate (intermediate) outcomes were sought, specifically 
durability of HBeAg seroconversion, loss of hepatitis B surface (HBsAg), long-term suppression 
of HBV DNA, and normalization of ALT.  
Eligibility Criteria:  
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We included randomized controlled trials (RCTs) and controlled observational studies that 
enrolled adults ≥18 years old diagnosed with chronic HBV infection who received antiviral 
therapy as treatment. We excluded studies that included patients with acute HBV infection, 
patients who were pregnant, patients co-infected with hepatitis C or D or human 
immunodeficiency virus, patients receiving corticosteroids, chemotherapy or immunosuppressive 
therapy, transplant recipients and hemodialysis patients, as well as studies without control or 
comparison groups. Supplemental Table 1 summarizes the inclusion and exclusion criteria for 
each key question.  
Search strategy:  
An experienced Mayo Clinic librarian conducted a comprehensive search of Medline In-Process 
& Other Non-Indexed Citations, MEDLINE, EMBASE, Cochrane Central Register of Controlled 
Trials, Cochrane Database of Systematic Reviews, and Scopus from early 1988 to September 
16th, 2014. Controlled vocabulary supplemented with keywords was used to search for 
comparative studies of antivirals for chronic hepatitis B. No language restrictions were used.  
Members from the AASLD HBV guideline methodology and writing committees helped identify 
additional studies. Supplemental Table 2 specifies the detailed search strategy.  
Study selections:  
Two reviewers independently screened titles and abstracts for potential eligibility using an online 
reference management system (DistillerSR, Evidence Partners, Inc.). Full text of the included 
abstracts were retrieved and screened in duplicate. Disagreements were resolved by seeking 
consensus or arbitration by a third reviewer. Inter-reviewer agreement (Kappa) was calculated 
during each screening level to assess agreement between reviewers. For PICO questions where 
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no studies meeting the predefined criteria were found, the AASLD HBV guideline methodology 
committee performed manual searches for uncontrolled observational studies. Data from these 
studies were summarized narratively and were in general consistent with low quality evidence.  
Data Extraction:  
Data extraction was done using a standardized, piloted form. We extracted data on study 
characteristics, patient characteristics, interventions details and outcomes of interest.  
Methodological quality and risk of bias assessment:  
We used the Cochrane Risk of Bias assessment tool and modified Newcastle-Ottawa Scale 
(NOS) to assess the risk of bias in RCTs and observational studies, respectively. Quality of 
evidence (i.e., certainty in the estimates) was evaluated using the Grading of Recommendations 
Assessment, Development, and Evaluation (GRADE) approach. Criteria used to evaluate quality 
of evidence were risk of bias, indirectness (surrogate outcomes), imprecision (wide confidence 
intervals), inconsistency (heterogeneity) and publication bias (6). 
Statistical analysis:  
For dichotomized outcomes, we calculated risk ratios and 95% confidence intervals (95%CI) 
using binomial distribution. We then pooled the log transformed risk ratios using the 
DerSimonian and Laird random-effects models and estimated heterogeneity using the Mantel- 
Haenszel model. To measure the overall heterogeneity across the included studies, we calculated 
the I² statistic, where I² >50% suggests high degree of heterogeneity. All statistical analyses were 
conducted using STATA, version 13 (StataCorp LP, College Station, TX). To explore 
heterogeneity, we conducted subgroup analysis for studies enrolling patients with more advanced 
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liver disease; we performed stratified analysis for the following groups: compensated cirrhosis, 
decompensated cirrhosis, acute on chronic liver failure, and severe acute exacerbations of 
chronic hepatitis B.  We explored the impact of publication bias by using the Egger regression 
asymmetry test and by constructing funnel plots if a sufficient number of studies (>20) per 
outcome was available and heterogeneity was low (7). 
Results: 
A total of 73 studies were included. Figure 1 describes the details of the selection process. 
Average weighted Kappa for study selection was 0.78. Controlled studies that reported the 
outcomes of interest were only available for questions 1, 2, 3 and 5. Uncontrolled studies that are 
relevant to questions 4, 6 and 7 are summarized in Supplemental File 3. Supplemental table 4 
provides the GRADE summary of the evidence.  
Question 1: Effectiveness of antiviral therapy in patients with immune active chronic HBV 
infection 
We included 59 studies (15 RCTs and 44 observational studies) that evaluated antiviral therapy 
and reported clinical outcomes. Forty-two studies compared antiviral therapy vs. control and 18 
studies compared one antiviral agent vs. another.  
1.1 Effectiveness of antiviral therapy compared to control in patients with chronic hepatitis B 
infection: 
Among 42 studies comparing antiviral therapy vs. control in 62,731 patients, 16 studies (8-23) 
compared IFN vs. no treatment; 16 studies (24-39) compared lamivudine vs. no treatment; 7 
studies (28, 40-45) compared entecavir vs. no treatment;1 study each compared telbivudine (44) 
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and tenofovir (46) vs. placebo and 3 studies (47-49) compared a variety of oral antiviral vs. no 
treatment. Eleven studies enrolled only patients with compensated cirrhosis, 5 studies enrolled 
only patients with acute on chronic liver failure, 2 studies enrolled only patients with 
decompensated liver disease, 3 studies enrolled only patients with severe acute exacerbations of 
chronic hepatitis B and 21 studies enrolled patients with stable chronic hepatitis B. Study 
characteristics are illustrated in Table 1. Risk of bias assessment for RCTs was low to moderate 
as 2 of the included RCTs reported the randomization method, 2 reported utilization of allocation 
concealment and 6 reported the blinding method used. Most of the observational studies were at 
high risk of bias due to lack of clear description of the selection process of the population and 
inadequate exposure and outcome ascertainment. Risk of bias is described in Tables 2-3.  
In 7 RCTs (8, 23-25, 29, 33, 46) involving 3,463 subjects with mean follow up of 28 months, 
antiviral therapy vs. control (Figure 2) significantly decreased the overall risk of decompensated 
liver disease (1 RCT, RR 0.4 (95% CI, 0.3 - 0.7)) and cirrhosis (1 RCT, RR 0.4 (95% CI,0.2 - 
0.8)). No significant differences were found in all-cause mortality (4 RCTs, RR 0.5 (95% CI, 0.2 
- 1.3), I
2
=72.9%) or HCC incidence (3 RCT, RR 0.6 (95% CI, 0.3 - 1.1), I
2
=0%). The quality of 
the evidence was low to moderate. One RCT (29) examined adverse events including death and 
decompensation as outcomes but no events were observed in either the intervention or control 
group.  
In 35 observational studies involving 59,201 patients with mean follow up of 60 months, meta-
analysis showed that antiviral therapy vs. control decreased the risk of HCC (23 studies, RR 0.5 
(95% CI, 0.4 - 0.7), I
2
=87.4%), all-cause mortality (23 studies, RR 0.6 (95% CI, 0.5 - 0.8), 
I
2
=92.3%) and cirrhosis (4 studies, RR 0.6 (95% CI,0.4 - 0.8), I
2
=0%) but did not significantly 
reduce the risk of decompensated liver disease (6 studies, RR 0.7 (95% CI, 0.3 - 1.9), I
2
= 96.5%) 
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when compared to untreated controls (Figures 3, 4 and 5). The quality of this evidence overall 
was low; however, these studies included large numbers of patients with long duration of follow-
up, yielding precise and narrow 95% CI. 
1.1.1 Effectiveness of antiviral therapy compared to control in the sub-group with stable chronic 
hepatitis B 
Of the 21 studies that enrolled patients with stable chronic hepatitis B, 0 to 91% of the 54,719 
patients included had compensated cirrhosis.  Reduction in risk of decompensated cirrhosis was 
shown in only 1 RCT and reduction in HCC in 11 observational studies. No studies demonstrated 
reduction in all-cause mortality. 
1.2 Effectiveness of antiviral therapy compared to control in patients with chronic HBV infection 
and compensated cirrhosis: 
In one RCT (25) enrolling 222 cirrhotic patients with follow up of 53 months, lamivudine vs. 
control reduced all-cause mortality (RR 0.1 (95% CI, 0.1-0.3), moderate quality evidence).  
In 10 observational studies (Figure 3) involving patients with compensated cirrhosis (mean 
follow up 60 months), antiviral therapy decreased the risk of HCC (10 studies, RR 0.6 (95% 
CI,0.4-0.8), I
2
=36.3%), decompensated liver disease (2 studies, RR 0.5 (95% CI,0.2-0.9), 
I
2
=67.2%) and all-cause mortality (3 studies, RR 0.5 (95% CI,0.4-0.6), I
2
=0%).  
In 5 observational studies (25, 26, 35, 38, 41) (Figure 4) with mean follow up of 84 months, IFN-
alpha compared to no treatment significantly decreased the risk of HCC (5 studies, RR 0.6 (95% 
CI, 0.4-0.9), I
2
=0%) but not of all-cause mortality (1 study, RR 0.7 (95% CI, 0.5-2.4), I
2
=56.9%) 
or decompensated liver disease (1 study, RR 0.7 (95% CI, 0.3-1.5).  
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In 4 observational studies (26, 35, 38, 41) (Figure 5) with mean follow up of 45 months, 
lamivudine vs. no treatment significantly reduced the risk of HCC (4 studies, RR 0.6 (95% CI, 
0.4-0.96), I
2
=49.9%), all-cause mortality (1 study, RR 0.4 (95% CI, 0.3-0.6) and decompensated 
liver disease (1 study, RR 0.3 (95% CI, 0.3-0.5).  In 1 cohort study (40) of 1,980 patients with 
cirrhosis followed for a mean of 52 months, entecavir vs. control reduced the risk of HCC (RR 
0.3 (95% CI, 0.1-0.5)) and death (RR 0.6 (95% CI, 0.3-0.98)). 
1.3 Effectiveness of antiviral therapy compared to control in patients with chronic HBV infection 
and decompensated cirrhosis: 
In 2 observational studies with follow up of 29 months (27, 32), lamivudine vs. control reduced 
all-cause mortality (2 studies, RR 0.5 (95% CI, 0.3-0.8) I
2
=0%). 
1.4 Effectiveness of antiviral therapy compared to control in patients with chronic HBV infection 
experiencing acute on chronic liver failure: 
In 1 RCT (46) involving 26 patients followed for a year, tenofovir reduced all-cause mortality 
(RR 0.5 (95% CI, 0.3-0.99), moderate quality evidence). In 4 observational studies (28, 37, 42, 
44) with mean follow up of 26 months, antiviral therapy vs. no therapy reduced all-cause 
mortality (RR 0.7 (95% CI, 0.6-0.8), I
2
=5.4%). Similarly, reduced mortality was also found in 
studies evaluating individual therapies including lamivudine (RR 0.8 (95% CI, 0.7-0.9), 
I
2
=50.2%) (28, 37, 44), entecavir (RR 0.7 (95% CI, 0.6-0.8), I
2
=0%) (28, 42, 44) and telbivudine 
(RR 0.4 (95% CI, 0.2-0.9) (44). 
1.5 Effectiveness of antiviral therapy compared to control in patients with chronic HBV infection 
with severe acute exacerbations: 
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In 3 observational studies (30, 43, 45) with more than 12 month mean follow up, meta-analysis 
of antiviral therapy vs. control showed no statistically significant reduction in all-cause mortality 
(RR 0.9 (95% CI, 0.5-1.5), I
2
=54.5%) which was consistent with studies evaluating the effect of 
individual agents: lamivudine (RR 0.5 (95% CI, 0.2-1.7) (30) and entecavir (RR 0.9 (95% CI, 
0.5-1.9), I
2
=71.3%) (43, 45). 
1.6 Head to head studies comparing individual antiviral agents: 
We included 8 RCTs (50-57) enrolling 2,318 patients and 10 observational studies (28, 58-66) 
enrolling 6,737 patients that compared one antiviral agent with another. We considered most of 
these RCTs (52, 55-57) to have high risk of bias due to unclear randomization methods, 
allocation concealment, blinding and loss to follow up. The observational studies were also 
limited by the unclear description of the characteristics for cohort selection, ascertainment of the 
outcomes and inadequate follow up. Tables 1-2 describe the details of the included studies and 
risk of bias. 
Among 5 studies enrolling 3,300 patients with chronic HBV infection and compensated cirrhosis 
(mean follow up 22 months), 1 RCT (55) compared adefovir vs. lamivudine, and 4 observational 
studies compared entecavir vs. lamivudine (58); entecavir vs. telbivudine (65); lamivudine vs. 
tenofovir (66); and telbivudine vs. lamivudine, respectively (61). Only 1 study (58) showed a 
significant difference in outcome with reduction in all-cause mortality in patients who received 
entecavir vs. lamivudine (1 study, RR 0.4 (95% CI, 0.3-0.6), very low quality of evidence). 
Four studies enrolled 607 patients with chronic HBV infection and decompensated cirrhosis 
(mean follow up 28 months). Three  RCTs compared entecavir vs. adefovir (57), adefovir vs. 
lamivudine (56), and telbivudine vs. lamivudine, respectively (50); and one cohort study (59) 
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compared entecavir vs. lamivudine. Reduction in risk of HCC was observed in the RCT (57) 
comparing entecavir vs. adefovir (RR 0.4 (95% CI, 0.2-0.8), and reduction in all-cause mortality 
was observed in the cohort study comparing entecavir vs. lamivudine (RR 0.4 (95% CI, 0.3-0.7) 
in patients who received entecavir. 
Three cohort studies (28, 62, 63) that enrolled 508 patients with acute on chronic liver failure and 
compared entecavir to lamivudine (mean follow up 32 months), showed no significant effect on 
all-cause mortality. 
Two cohort studies (60, 64) that compared entecavir vs. lamivudine in 320 patients with severe 
acute exacerbation of chronic hepatitis B (mean follow up 32 months) showed no significant 
effect on mortality. 
Question 2. Effectiveness of antiviral therapy in patients with immune tolerant chronic HBV 
infection 
Two studies (67) (68) evaluated antiviral therapy in HBeAg-positive patients with normal ALT 
levels. Detailed study characteristics and risk of bias are described in Tables 1-2. 
One RCT (67) compared tenofovir (64 patients) to a combination of tenofovir and emtricitabine 
(62 patients) for 192 weeks. Although no long-term clinical outcomes were reported, tenofovir 
and emtricitabine vs. tenofovir showed a statistically significant increase in viral suppression 
(RR 1.4 (95%CI, 1.1 - 1.8), moderate quality evidence) but no statistically significant increase in 
HBeAg loss (RR 0.3 (95%CI, 0.03- 2.2)), HBeAg seroconversion (RR 0.1 (95%CI, 0.01-2.8)) or 
HBsAg clearance (RR 1.0 (95%CI, 0.3-3.9)). The quality of evidence was low due to 
indirectness and imprecision. 
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In a cohort study (68) of 68 HBeAg positive postpartum women, Peg IFN and adefovir vs. 
untreated control significantly improved rates of HBeAg seroconversion (RR 41.8 (95% CI, 2.6 - 
666.9)) and HBeAg loss (RR 20.3 (95% CI, 1.2 - 337.7)). The quality of evidence was very low, 
down rated due to observational nature of the study, risk of bias and imprecision.  
Question 3: Discontinuing compared to continuing antiviral therapy in HBeAg positive patients 
who seroconverted from HBeAg to anti-HBe 
Two observational studies (69, 70) compared patients with chronic hepatitis B who stopped 
therapy (61 patients) after HBeAg seroconversion to those who continued (128 patients) to 
receive antiviral therapy. For both studies, the median (range) duration of therapy leading to 
HBeAg seroconversion was 21 (1-120) months, median follow up after stopping therapy was 40 
(range 2-120) months and median duration of consolidation treatment after HBeAg 
seroconversion was 12 (range 1-55) months. Characteristics and risk of bias for both studies are 
illustrated in Tables 1 and 3.  
Compared to continued antiviral therapy, very low quality evidence suggests increased risk of 
relapse of viremia in patients who stopped antiviral therapy RR 94.4 (95% CI, 13.3-670.7),  
I
2
=0%) with no effect on ALT flares. The rate of HBeAg seroreversion was 8% after a median of 
6 months in 1 study (69) and a cumulative incidence of 9% at 5 years in another study (70). No 
clinical outcomes were reported. The quality of evidence was very low due to increased risk of 
bias, indirectness and imprecision. Additional non comparative and indirect evidence is 
summarized in Supplemental File 3. 
Question 4. Stopping compared to continuing antiviral therapy in HBeAg negative adults with 
immune active chronic HBV infection  
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We were unable to find comparative studies for this question. Supplemental File 3 summarizes 
uncontrolled studies and indirect evidence that may address this question. Data from these 
studies indicate a high rate of viral relapse when treatment was stopped, but rates of clinical 
relapse were lower.  
Question 5. Safety of entecavir compared to tenofovir 
Eleven studies (1 RCT (71) and 10 observational studies (66, 72-74) (75-80)) compared 
entecavir vs. tenofovir in 1,300 patients with mean follow up of 18.6 months. Characteristics of 
the included studies and risk of bias are described in Table 1-2.  
Meta-analysis of the studies included showed no statistically significant difference between 
entecavir and tenofovir in renal safety profiles or hypophosphatemia, but duration of observation 
was short. No studies reported on bone density. Table 4 describes the detailed outcomes reported 
for each study.  
Question 6. Adding a second antiviral agent compared to continuing monotherapy (entecavir or 
tenofovir) in patients with chronic HBV infection and persistent viremia 
We were unable to identify comparative studies for this question. Uncontrolled studies and 
indirect evidence (Supplemental File 3) showed little to no benefit in adding a second antiviral 
agent compared to continuing monotherapy with entecavir or tenofovir.  
Question 7. Antiviral therapy in patients with chronic HBV infection and compensated cirrhosis 
and low level viremia (HBV DNA <2000 IU/ml) 
We were unable to identify comparative studies on outcomes of these patients with or without 
antiviral therapy. Supplemental File 3 summarizes uncontrolled studies and indirect evidence 
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that address this question. In patients with compensated cirrhosis and low level viremia, one 
study specifically examined the benefit of antiviral therapy and found a decrease in incidence of 
HCC but the results could be confounded by differences in the characteristics of treated versus 
untreated patients (81).  
Publication bias:  
We were unable to evaluate publication bias due to high heterogeneity and small number of 
studies for each outcome.  
Discussion: 
The members of the AASLD methodology and writing committees for the HBV Practice 
Guideline developed seven key clinical questions that challenge clinicians and patients in daily 
practice. The methodologists performed an extensive literature search, selected studies that 
included a comparison group and data on clinical outcomes, and then rated the quality of the 
evidence. Sufficient comparative evidence was found for four of the key questions, but evidence 
was sparse or absent for the remaining three questions: when to stop therapy in persons with 
immune active chronic HBV infection who are HBeAg-negative, the benefit of adding either 
entecavir or tenofovir in persons who fail to suppress HBV DNA to undetectable levels with 
either of these drugs alone, and whether antiviral therapy should be used in patients with 
compensated cirrhosis and HBV DNA levels below 2,000 IU/ml.  For these three questions, the 
committee identified indirect and non-comparative evidence (Supplemental File 3).  
Antiviral therapy in patients with immune active chronic HBV infection had 59 published studies 
available for review and evaluation. Moderate to low quality evidence supported the benefit of 
therapy in reducing adverse outcomes of chronic HBV infection including progression to 
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cirrhosis, liver decompensation and all-cause mortality. Because the observational studies had 
more patients (59,201 vs. 3,463) and longer follow-up (60 vs. 28 months), data on mortality and 
HCC from 35 observational studies were sufficiently precise, whereas data from 7 RCTs were 
imprecise. These larger sample sizes and longer follow-up in the observational studies account 
for the significant benefit of antiviral treatment on HCC and mortality found in the observational 
studies but not in the RCTs.  
Given the indolent nature of chronic HBV infection, it is not surprising that evidence supporting 
the benefit of antiviral treatment on clinical outcomes was found only when the analysis was 
limited to patients with more advanced disease: compensated cirrhosis, decompensated cirrhosis 
or acute on chronic liver failure. Indeed, most RCTs of antiviral therapy in chronic HBV 
infection enrolled only or mostly patients with no cirrhosis, and very few trials that enrolled 
predominantly patients with no cirrhosis provided data on clinical outcomes. Provision of 
evidence to support that antiviral therapy improves clinical outcomes in patients with chronic 
HBV infection and no cirrhosis would require thousands of patients followed for many years, 
and withholding treatment in the control group until the completion of the study. Such a study 
would be unethical and likely infeasible. Thus, evidence supporting the benefit of antiviral 
therapy in patients without cirrhosis has to rely on intermediate outcomes such as HBV DNA 
suppression, ALT normalization, HBeAg seroconversion, HBsAg loss, and cirrhosis prevention 
or regression. These intermediate outcomes have been shown to correlate with improvement in 
clinical outcomes and represent a series of steps towards the ultimate goal of improving clinical 
outcome. For example, HBV DNA suppression precedes HBeAg seroconversion which precedes 
HBsAg loss; and HBsAg loss has been shown to be associated with decreased risk of HCC, 
particularly if it occurs before the development of cirrhosis.  
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Recent studies showed that high levels of HBV viremia are associated with an increased risk of 
cirrhosis, HCC and liver-related mortality (82-84). Patients in the immune tolerant phase have 
the highest level of viremia. In the two studies exclusively enrolling patients in the immune 
tolerant phase, clinical outcomes were not reported, but rates of intermediate outcomes were 
lower than those in patients in the HBeAg-positive immune active phase. 
In the two observational studies comparing the risk of viral relapse and HBeAg seroreversion in 
HBeAg-positive patients who achieved HBeAg seroconversion during nucleos(t)ide analogue 
therapy and who stopped vs. continued therapy, very low quality evidence suggests an increased 
risk of relapse of viremia with stopping. Other observational studies (see Supplemental File 3) 
showed durable HBeAg seroconversion varying from 20-90% depending on the duration of 
consolidation therapy after achieving HBeAg seroconversion, the most consistent predictor of 
durable response. Studies directly comparing stopping vs. continuing therapy in HBeAg-negative 
patients on nucleos(t)ide analogue therapy were not found; however, observational studies in the 
literature on the virologic, serologic and biochemical outcomes of patients who stopped therapy 
showed that viral relapse is universal but that sustained clinical remission and even HBsAg loss 
is possible (see Supplemental File 3). Because hepatitis flares and hepatic decompensation may 
occur after stopping treatment, close monitoring after discontinuation of treatment is important, 
especially for those with cirrhosis at the start of therapy who have the highest risk for 
decompensation. 
Entecavir and tenofovir have been used as first-line nucleos(t)ide analogues because of their 
potent antiviral activity and low risk of antiviral drug resistance. Tenofovir can cause impairment 
in renal function, renal tubular dysfunction including Fanconi anemia, and decreased bone 
mineral density. Meta-analysis of studies comparing monotherapy with entecavir or tenofovir did 
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not show a significant difference in serum creatinine level, estimated glomerular filtration rate or 
in serum phosphate level; however, the duration of treatment was short in these studies.  
While entecavir and tenofovir have potent antiviral activity, some patients have persistent 
viremia despite being adherent to medication. This is more common among HBeAg-positive 
patients with high baseline serum HBV DNA. Studies comparing continuing entecavir or 
tenofovir monotherapy vs. adding a second antiviral agent in patients with persistent viremia 
were not found. Observational studies of patients who continued entecavir or tenofovir 
monotherapy showed that most patients ultimately achieved undetectable HBV DNA.  
Patients with compensated cirrhosis have a high risk of liver failure and HCC particularly those 
with high levels of HBV DNA. The benefit of antiviral therapy in patients with compensated 
cirrhosis and low levels of HBV DNA has not been established. One retrospective study 
comparing outcomes of patients with compensated cirrhosis and low levels of HBV DNA 
(<2,000 IU/ml) with or without antiviral therapy suggest a benefit of antiviral therapy in 
decreasing the incidence of HCC, but patients who received treatment differed substantially from 
those who did not receive treatment and in most patients HBV DNA was level was higher than 
2,000 IU/ml at the time treatment was started (81). 
Several questions that had been addressed in the previous AASLD HBV Guidelines were not 
included in this systematic review: who should be screened for HBV infection, who should be 
vaccinated against HBV, what clinical and laboratory criteria (levels of HBV DNA and ALT) 
should be used to initiate antiviral therapy, who should undergo surveillance for HCC, and how 
frequently patients with chronic HBV infection who are not receiving antiviral therapy should be 
monitored. Management of special population such as those with HIV, HCV or HDV 
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coinfection, and those requiring immunosuppressive therapy were also not addressed in the 
current review because data from controlled studies for these patient populations were sparse. 
Additional recommendations can be found in the previous AASLD HBV Guideline, the Centers 
for Disease Control and Prevention and the World Health Organization Guidelines (85-88).  
Conclusion: Most of the current literature focuses on the immune active phases of chronic HBV 
infection. Decision-making in other commonly encountered and challenging clinical settings 
depends on indirect evidence. In addition to evidence-based data, management of patients with 
chronic HBV infection should take into consideration individual patient preference and available 
resources. Recommendations for management of adults with chronic HBV infection based on 
this systematic review are provided in the updated AASLD guidelines (89).   
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1998(21) 
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40 IFN-alpha 47±1.8 40 
5.3 
(0.61xULN) 
NR 74.4 100 
Cohort 
50 Control 45 ± 2.2 50 
5.3 
(0.61xULN) 





210 IFN –alpha 36 210 
100% 
elevated ALT 
NR 15.6 19 
RCT 




89 Lamivudine 39±11 6 
2.1±1.7 
(xULN) 
5 ±0.0.9 120 31 
RCT 



















27 Lamivudine 40 NR NR NR 63.6 100 
Cohort 







42 45% NR NR 48 100 
Case 
Control 





























































28 Lamivudine 42.7±13.5 16 1416.6±577.7 NR 12 NR 
Cohort 
 



























































































37.3±12.4 1272 163.5±234.3 NR 74.4±66 15.5 
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51 Lamivudine NR 12 NR NR 35 100 
Cohort 
 



































130 Lamivudine 44.3±3.5 90 474.1±83.4 > 4.3 3 10 
Cohort 
 
























872 Lamivudine 40.1±12.2 694 
161±183.8 
 
7.1±0.4 56.4±28.8 47.4 
Cohort 
 
699 Control 35.5±12.9 637 
141.3±199.1 
 





1466 Entecavir 51±12 443 
145±319 
 
5 36 ±13 100 
Cohort 
424 Control 41±13 155 
84 ±113 
 


















































39 Entecavir NR NR NR NR NR NR 
Cohort 
 










40.6±11.4 NR 534±712.8 4.3 NR NR 
Cohort 
 






55 Entecavir 43.6±10.9 14 
357±405.2 
 
5±0.65 3 NR 
Cohort 
 















































variety of oral 
antiviral 
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37 Control 41.03±11.5 11 
287 
(17–2535) 
5± 0.9 0.2-41.5 NR 
Chan, 2012(50) China 
114 Telbivudine 49.6±10.9 61 
75.1±54.4 
 
6.9 ± 1.2 24 100 
RCT 
114 Lamivudine 51.9±10 55 
84 ± 87.8 
 






354 Entecavir 35±13 348 140.5±114.3 8.9±1.3 12 8 
RCT 
 





325 Entecavir 44±11 3 141±114.7 6.9±1.1 12 5 
RCT 
 


















































181 Lamivudine 40±11.1 0 105.7±128.2 6.5±1.1 18 29 
Wang, 2013(55) China 
102 Adefovir 44±9.5 NR 
72.76 ± 61.8 
 
6.2 ± 1.2 24 100 
RCT 
104 Lamivudine 44.9±10.03 NR 
72.6±46.4 
 





32 Adefovir 31-62 NR NR NR NR 100 
RCT 
 




100 Entecavir 51±1.2 54 99.2± 11.1 6.8±0.01 24 100 
RCT 
 
91 Adefovir 53±1.1 50 
100± 8.6 
 
7.5±0.01 24 100 
Lim, 2014(58) Korea 















Hsu, 2012(59) Taiwan 
53 Entecavir 48 (40-56) 18 
467 
(78-879) 
6.1 12 45.3 
Cohort 
73 Lamivudine 46 (37-58) 17 
391 
(68-1530) 




36 Entecavir 51±13 13 
1151±724 
 
6.6±1.4 18. ±12 14 
Cohort 












40 Telbivudine 51.8±10.7 20 NR 5.8±0.6 12 100 
Cohort 
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65 Entecavir 42.8±13.1 21 352.5± 77.2 















53 Entecavir 49±13 15 
1287± 788 
 
8.2± 6.8 4 NR 
Cohort 
 





88 Telbivudine 55.7±11.4 20 
102.5± 137.5 
 
5.1± 0.5 27.6 100 
Cohort 
 
88 Entecavir 56.1±9.8 17 125.8± 179 5.3±0.4 53.1 100 
Koklu, 2013(66) Turkey 
72 Tenofovir 54.2±10.5 9 
115.2±217.1 
 
4.9± 1.2 12 100 
Cohort 76 Entecavir 54.2±11.2 17 
86.2± 115.6 
 
5± 1.2 12 100 
74 Lamivudine 56.8±11.4 10 
53.2±44.5 
 
4 ± 1.3 12 100 















33 ±11.2 62 
26.2 ±9.88 
 
8.4 ± 0.4 48 NR 
Lu, 2015(68) China 
30 
Peg-IFN and  
Adefovir 




38 Control 26.8 ± 3.1 30 6 NR 




















7±1.2 12 NR 







32 (21 – 55) NR 
158 
(21 – 2069) 
 
7.9 







(46 – 1670) 
 
8.7 
(6.4 – 10.2) 
45 NR 
Question 5. Safety of entecavir compared to tenofovir: 
Koklu, 2013(66) Turkey 
54 Tenofovir 54.2±10.2 9 
115.2±217.1 
 
4.9±1.2 21.4±9.7 100 
Cohort 
60 Entecavir 52.4±11.2 17 
86.2±115.6 
 
5±1.2 24.0±13.3 100 






































Turkey 65 Tenofovir NR 29 
114±181 
 
7±6.9 12 NR Cohort 
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29 Entecavir NR 10 
84±69 
 




90 Tenofovir 43.3±12.9 29 
116.7±92.6 
 
7.6±4.6 30.2± 15.7 NR 
Cohort 
105 Entecavir 42.0±11.2 36 
120±96.6 
 

















































Hung, 2015(76) Taiwan 
41 Tenofovir 49.8±13.1 NR 
1104 ±918 
 
6.3±1.2 6 20 
Cohort 
148 Entecavir 50.6±14.7 NR 
1084 ±830 
 
5.8±1.2 6 34 















































Tien, 2014(79) USA 
42 Tenofovir 49 ±12 11 NR NR 26 ± 13 20 
Cohort 
44 Entecavir 51 ±9 8 NR NR 32 ± 24 10 
















(1 – 55) 
NR 
IFN=interferon, NR=not reported, RCT=randomized controlled trial, ULN=upper limit of normal 
*Baseline HBV DNA in studies that used different units were converted using the formulas: 1 copy = 0.2 IU and 1 pg = 283,000 copies or 56,000 IU 
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Attrition Bias or 




Question 1: Effectiveness of antiviral therapy compared to control  in patients with immune active chronic HBV infection (Antiviral vs control): 
Anderson , 
1987 (8) 
NR NR Yes Yes Yes NR NR 
Krogsgaard, 
1998 (23) 
NR NR Yes Yes Yes NR NR 
Chan, 2007(24) 
Randomized /Randomization was 
centralized and stratified according to the 
geographical regions. 
NR Yes Yes Yes No 
More than 15% 
 
Eun, 2007 (25) 
Randomized 
 













Randomization was done with a random 
number table. 
Yes Yes Yes NR 
No 
 
Less than 10% 




Centralized, stratifying based on screening 
CPT score and ALT level. 
Yes Yes Yes Yes No 







NR Yes Yes Yes NR NR 
Lai, 2006 (52) Randomized NR Yes NR Yes NR NR 
Lau, 2005 (53) 
Randomized /Centralized and stratified 
according to geographic region and ALT 
levels. 
NR NR NR NR NR NR 
Marcellin, 
2004(54) 
Randomized /Centralized and stratified 
according to geographic region and ALT 
levels. 
 
NR Yes Yes Yes NR NR 
Wang, 2013 
(55) 
Randomized NR NR NR NR No NR 
Yang, 2009 
(56) 
Randomized NR NR NR NR NR 
Less than 10% 
 
Liaw, 2011(57) 
Randomized / Randomization was not 





No No No 
Less than 10% 
 
Question 2. Effectiveness of antiviral therapy in patients with immune-tolerant chronic HBV infection 
Chan, 2014(67) Randomization NR Yes Yes NR None Less than 10% 




Randomization NR Yes Yes NR None Less than 10% 
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Table 3: Risk of bias assessment for the included non-randomized studies:  
Author name, year 






Adequacy of follow 
up 
Funding 
sources Exposed cohort 
Non-exposed 
cohort/control 
Question 1: Effectiveness of antiviral therapy compared to control  in patients with immune active chronic HBV infection (Antiviral vs control): 
IIHCSG, 1998 (9) Selected group of users 
No description of the 
derivation of the non-
exposed cohort 
No description No description NR NR 
Lin, 2007 (10) Selected group of users 
No description of the 
derivation of the non-
exposed cohort 
No description No description NR NR 
Truong, 2005 (11) 
Somewhat 
representative of the 
community or 
population 
Drawn from the same 
community as the 
exposed cohort 
Secure records Record linkage NA NR 
Tangkijvanich, 2001 
(12) 
Selected group of users 
No description of the 
derivation of the non-
exposed cohort 




No description of the 
derivation of the non-
exposed cohort 
Secure records Record linkage Complete follow-up NR 
Niederau, 1996 (14) Selected group of users 
No description of the 
derivation of the non-
exposed cohort 
No description No description NR NR 
Lin, 2004 (15) 
Somewhat 
representative of the 
community or 
population 
Drawn from a 
different community 
or population as the 
exposed cohort 
Secure records Record linkage Complete follow-up Reported 
Benvegnu, 1998 (16) No description No description No description No description NR NR 
Tong, 2006 (17) No description No description No description No description NR NR 
Di Marco, 1999 (18) No description No description No description No description NR NR 
Brunetto, 2002 (19) No description No description No description No description NR NR 
Mahmood, 2005 (20) Selected group of users 
No description of the 
derivation of the non-
exposed cohort 
No description No description NR NR 
Ikeda, 1998 (21) Selected group of users 
No description of the 
derivation of the non-
exposed cohort 
No description No description NR NR 
Fattovich, 1997(22) Selected group of users 
No description of the 
derivation of the non-
exposed cohort 
Secure records Record linkage NR NR 
Tong, 2009 (26) Selected group of users 
No description of the 
derivation of the non-
exposed cohort 
No description No description NR NR 
Das, 2010 (27) 
 
Selected group of users 
No description of the 
derivation of the non-
exposed cohort 
No description No description NR NR 
Cui, 2010 (28) 
Truly representative of 
the community or 
population 
Drawn from the same 
community as the 
exposed cohort 
Secure records Record linkage Complete follow-up NR 
Chan, 2002(30) Selected group of users 
Drawn from a 
different community 
or population as the 
exposed cohort 
Secure record Record linkage NR NR 
Lok, 2003 (31) 
Somewhat 
representative of the 
community or 
population 
Drawn from the same 
community as the 
exposed cohort 
Secure records Record linkage 
Follow-up rate < 
90% and no 
description of the 





Selected group of users 
No description of the 
derivation of the non-
exposed cohort 
No description No description NR NR 
Matsumoto, 2005 (34) 
 
Truly representative of 
the community or 
population 
Drawn from the same 
community as the 
exposed cohort 
Secure records Record linkage NA Reported 
Ma, 2007 (35) No description 
Drawn from the same 
community as the 
exposed cohort 
No description No description NR NR 
Yuen, 2007 (36) 
Truly representative of 
the community or 
population 
Drawn from a 
different community 
or population as the 
exposed cohort 
Secure records Record linkage 
Follow-up rate < 
90% and no 
description of the 
reasons for loss to 
Reported 
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Sun, 2010 (37) 
Truly representative of 
the community or 
population 
Drawn from the same 
community as the 
exposed cohort 
Secure records Record linkage Complete follow-up NR 
Kim, 2012 (38) 
Truly representative of 
the community or 
population 
Drawn from the same 
community as the 
exposed cohort 
Secure records Record linkage Complete follow-up Reported 
Eun, 2010 (39) 
Truly representative of 
the community or 
population 
Drawn from the same 
community as the 
exposed cohort 
Secure records Record linkage Complete follow-up Reported 
Wong, 2013 (40) 
Somewhat 
representative of the 
community or 
population 
Drawn from the same 
community as the 
exposed cohort 
No description No description NR NR 
Hosaka, 2013 (41) 
Somewhat 
representative of the 
community or 
population 
Drawn from the same 
community as the 
exposed cohort 
No description No description NR NR 
Lin, 2013 (42) 
Truly representative of 
the community or 
population 
Drawn from the same 
community as the 
exposed cohort 
Secure records Record linkage 
Subjects lost to 
follow-up unlikely to 
introduce bias, small 
number lost to 
follow-up 
Reported 
Xiao, 2009 (43) 
No description of the 
derivation of the cohort 
Drawn from the same 
community as the 
exposed cohort 
No description No description NR NR 
Xu, 2009 (44) 
Truly representative of 
the community or 
population 
No description of the 
derivation of the non-
exposed cohort 




representative of the 
community or 
population 
Drawn from the same 
community as the 
exposed cohort 





Wu, 2014 (47) 
Truly representative of 
the community or 
population 
Drawn from the same 
community as the 
exposed cohort 
Secure records Record linkage NR NR 
Gordon, 2014(48) 
Truly representative of 
the community or 
population 
Drawn from the same 
community as the 
exposed cohort 
Secure records Record linkage NR Reported 
Kumada, 2013 (49) 
Truly representative of 
the community or 
population 
Drawn from the same 
community as the 
exposed cohort 
Secure records Record linkage NR Reported 
Question 1. Head to head studies comparing individual antiviral agents: 
Cui, 2010 (28) 
Truly representative of 
the community or 
population 
Drawn from the same 
community as the 
exposed cohort 
Secure records Record linkage Complete follow-up NR 
Lim,2014 (58) Selected group of users 
Drawn from a 
different community 
or population as the 
exposed cohort 
Secure records Record linkage Complete follow-up Reported 
Hsu, 2012(59) 
Somewhat 
representative of the 
community or 
population 
Drawn from the same 
community as the 
exposed cohort 
Secure records No description NR Reported 
Wong, 2011 (60) 
Truly representative of 
the community or 
population 
Drawn from the same 





Follow-up rate < 
90% and no 
description of the  
reasons for loss to 
follow-up 
Reported 
Liang, 2009 (61) No description 
Drawn from the same 
community as the 
exposed cohort 
Secure records No description Not reported NR 
Chen, 2014 (62) 
Somewhat 
representative of the 
community or 
population 
Drawn from the same 
community as the 
exposed cohort 
Secure records. Record linkage NR Reported 
Zhang, 2014 (63) 
No description of the 
derivation of the cohort 
No description of the 
derivation of the non-
exposed cohort 
Secure records Record linkage 
Follow-up rate < 
90% and no 
description of the  
reasons for loss to 
follow-up 
NR 
Tsai, 2014 (64) Selected group of users 
Drawn from a 
different community 






Tsai, 2014(65) Truly representative of Drawn from the same Secure records Record linkage Follow-up rate < Reported 
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the community or 
population 
community as the 
exposed cohort 
90% and no 
description of the 
reasons for  loss to 
follow-up 
Koklu, 2013 (66) 
Truly representative of 
the community or 
population 
Drawn from the same 
community as the 
exposed cohort 
Secure records Record linkage Complete follow-up NR 
Question 2. Effectiveness of antiviral therapy in patients with immune-tolerant chronic HBV infection 
Lu 2015 (68) Selected group of users 
Drawn from the same 
community as the 
exposed cohort 
Secure records Record linkage NR NR 
Question 3: Discontinuing vs continuing antiviral therapy in HBeAg positive patients who seroconverted from HBeAg to anti-HBe 
Chaung, 2012 (69) Selected group of users 
Drawn from the same 
community as the 
exposed cohort 
Secure records Record linkage NR NR 
Fung, 2009 (70) Selected group of users 
Drawn from the same 
community as the 
exposed cohort 
Secure records Record linkage NR NR 
Question 5. Safety of entecavir compared to tenofovir: 
Koklu, 2013 (66) Selected group of users 
Drawn from the same 
community as the 
exposed cohort 
Secure records Record linkage NR NR 
Dogan, 2012 (72) Selected group of users 
Drawn from the same 
community as the 
exposed cohort 
Secure records Record linkage NR NR 
Batirel, 2014 (73) Selected group of users 
Drawn from the same 
community as the 
exposed cohort 
Secure records Record linkage NR NR 
Cholongitas, 2015 (74) Selected group of users 
Drawn from the same 
community as the 
exposed cohort 
Secure records Record linkage NR NR 
Huang, 2015 (75) Selected group of users 
Drawn from the same 
community as the 
exposed cohort 
Secure records Record linkage NR NR 
Hung, 2015 (76) Selected group of users 
Drawn from the same 
community as the 
exposed cohort 
Secure records Record linkage NR NR 
Mallet, 2014 (77) Selected group of users 
Drawn from the same 
community as the 
exposed cohort 
Secure records Record linkage NR NR 
Mauss, 2011 (78) Selected group of users 
Drawn from the same 
community as the 
exposed cohort 
Secure records Record linkage NR NR 
Tien, 2014 (79) Selected group of users 
Drawn from the same 
community as the 
exposed cohort 
Secure records Record linkage NR NR 
Gish, 2012 (80) Selected group of users 
Drawn from the same 
community as the 
exposed cohort 
Secure records Record linkage NR NR 
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Table 4: Outcomes reported for Tenofovir vs. Entecavir in chronic HBV infection: 







Renal impairment 1/72 0/77 
3.21 
(0.13, 77.44) 
Hypophospothamia 1/72 0/77 
3.21 
(0.13, 77.44) 
Increase of creatinine kinase 0/72 1/77 
0.36 
(0.01 , 8.60) 
Liaw, 2011(68) 















eGFR <50 mL/min 3/31 2/21 
1.02 
(0.19, 5.57) 
Serum phosphate levels NR NR NA 
Hung, 2015(72) 





Reduction of estimated GFR 




















Mean eGFR variation 
0.6 (-0.8 to 1.94) 
 

















Phosphate threshold for renal tubular 




GFR by Cockcroft Gault < 60 mL/min 1/42 2/44 
0.52 
(0.05, 5.56) 
GFR by MDRD < 60 mL/min 1/42 2/44 
0.52 
(0.05, 5.56) 
Serum phosphate (mg/dL) < 2.8 mg/dL 6/42 2/44 
3.14 
(0.67, 14.71) 
Serum creatinine (mg/dL) >1.5 mg/dL 0/42 0/44 NA 






Confirmed SCr increase 0.5 mg/dL 3/80 11/80 
0.27 
(0.08, 0.94) 





Decrease in eGFR 20% (MDRD) 33/80 35/80 
0.94 
(0.66, 1.35) 
NR: not reported; NA: not available; SCr: serum creatinine; CK: creatine kinase; eGFR: estimated glomerular 
filtration rate 
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leSupplemental Table 1: Inclusion and exclusion criteria for each key question  
Definition of disease Chronic HBV infection in adults ≥ 18 year old (detectable HBsAg in serum for >6 months) 


































Stopped antiviral therapy 













Clinical outcomes: Cirrhosis, decompensated liver disease, HCC and death 
Intermediate outcomes (if evidence on clinical outcomes is limited or unavailable): HBsAg loss, HBeAg seroconversion and 
HBeAg loss 
Q3-4: Cirrhosis, decompensated liver disease, HCC, relapse (viral and clinical) and  HBsAg loss 
Q5: Renal function, hypophosphatemia and bone density 
Q6: Resistance, flare/decompensation and HBeAg loss 
Q7: Clinical outcomes: Cirrhosis, decompensated liver disease, HCC and death 
Study design RCT and controlled observational studies 
Exclusions 
Acute HBV infection, children and pregnant women, HIV (+), HCV (+) or HDV (+) persons or other special populations 
such as hemodialysis, transplant, and treatment failure populations. Co treatment with steroids and uncontrolled studies. 
 

























Supplemental Table 2: Detailed Search Strategy: 
Ovid 
Database(s): Embase 1988 to 2014 Week 37, Ovid MEDLINE(R) In-Process & Other Non-
Indexed Citations and Ovid MEDLINE(R) 1946 to Present, EBM Reviews - Cochrane Central 
Register of Controlled Trials August 2014, EBM Reviews - Cochrane Database of Systematic 
Reviews 2005 to July 2014  
Search Strategy: 
# Searches Results 
1 exp Hepatitis B/dt 26410 
2 ("hepatitis B" or "serum hepatitis" or "hippie hepatitis" or "injection hepatitis" or "hepatitis type B").mp. 178548 
3 1 or 2 178548 
4 exp Antiviral Agents/ 916254 
5 exp antivirus agent/ 612059 
6 
("1-Deoxynojirimycin" or absouline or "abt 333" or "abt 450" or Acetylcysteine or 
aciclovir or "acyclouridine derivative" or Acyclovir or "adenine xyloside" or 
"adenosine dialdehyde" or afovirsen or "al 721" or alamifovir or alisporivir or "aln 
rsv 01" or "alvircept sudotox" or amantadine or amenamevir or amidapsone or 
amitivir or "ammonium trichloro dioxyethylene o o tellurate" or amsacrine or "ana 
975" or "anti viral agent" or AntiRetroviral* or "Anti-Retroviral*" or antiretrovirus 
or antiviral* or "anti-viral*" or Aphidicolin or arasangivamycin or arbidol or 
arildone or astodrimer or asunaprevir or avarol or avarone or avridine or "azd 
7295" or balapiravir or bavituximab or "behenyl alcohol" or benzimidavir or 
besifovir or boceprevir or bonaphthone or "Brefeldin A" or brincidofovir or 
Bromodeoxyuridine or bropirimine or buciclovir or carbocyclic or carbodine or 
carrageenan or cidofovir or ciluprevir or clevudine or "cpg 10101" or crofelemer or 
cyclaradine or "cyclosporin A" or cytarabine or daclatasvir or damavaricin or 
danoprevir or dasabuvir or deitiphorin or deleobuvir or denotivir or 
deoxyaristeromycin or Deoxyglucose or deoxypenciclovir or deoxyribavirin or 
desciclovir or detiviciclovir or "didemnin A" or "didemnin B" or 
Dideoxyadenosine or Dideoxynucleoside* or disoxaril or "distamycin 5" or 
"distamycin A" or Ditiocarb or droxinavir or edoxudine or elbasvir or "enisamium 
iodide" or enviroxime or epetirimod or eudistomin or exbivirumab or faldaprevir or 
famciclovir or favipiravir or felvizumab or fiacitabine or fialuridine or filibuvir or 
Filipin or florenal or "flucytosine arabinoside" or fomivirsen or foravirumab or 
fosarilate or foscarnet or fosdevirine or fucoidin or "gamma venin" or ganciclovir 
or "gene expression modulator" or grazoprevir or "gs 9256" or "guanine 7 oxide" 
or hypericin or "hypoxanthine arabinoside" or idoxuridine or "idoxuridine 
derivative" or "idx 184" or imexon or imiquimod or "Inosine Pranobex" or 
iododeoxycytidine or ipilimumab or isatoribine or "isis 13312" or "isis 14803" or 
laninamivir or larifan or ledipasvir or letermovir or levovirin or lexithromycin or 
libivirumab or litomeglovir or lomibuvir or mericitabine or merimepodib or 
Methisazone or methisoprinol or methylcytidine or metisazone or miravirsen or 
747988 
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moroxydine or motavizumab or "mycophenolic acid" or "Myxovirus resistance 
protein" or "n bromoacetyldistamycin A" or narlaprevir or neceprevir or 
"neominophagen C" or nesbuvir or netivudine or netropsin or nivocasan or 
omaciclovir or ombitasvir or oseltamivir or palivizumab or penciclovir or 
"penciclovir triphosphate" or peramivir or "phosphonoacetic acid" or 
"Phosphonoacetic Acid" or pirazofurin or pirodavir or pleconaril or pocapavir or 
"pokeweed antivirus protein" or "Poly A-U" or "Poly I-C" or pritelivir or 
pseudohypericin or "pyran copolymer" or "Pyran Copolymer" or radavirsen or 
rafivirumab or "recombinant intercellular adhesion molecule 1" or regavirumab or 
resiquimod or ribavirin or "ribavirin derivative" or rifabutin or rimantadine or 
rintatolimod or riodoxol or rociclovir or rupintrivir or samatasvir or sangivamycin 
or "sangivamycin derivative" or "scopadulcic acid B" or setrobuvir or sevirumab or 
simeprevir or sofosbuvir or sorivudine or sovaprevir or streptovaricin or 
Streptovaricin or streptovirudin or suramin or suvizumab or synadenol or 
synguanol or taribavirin or tebrofen or tecovirimat or tegobuvir or telaprevir or 
telbivudine or "Tenuazonic Acid" or "thiarubrine A" or "thiophene A" or "thymine 
arabinoside" or tilorone or Tilorone or "tilorone derivative" or tiviciclovir or 
tomeglovir or torcitabine or trifluridine or tromantadine or tunicamycin or 
tuvirumab or umifenovir or "uracil arabinoside" or valaciclovir or valganciclovir or 
valomaciclovir or valopicitabine or valtorcitabine or vaniprevir or vapendavir or 
vedroprevir or vidarabine or Vidarabine or viracine or "viral inhibitor*" or 
virantmycin or virostatic* or viroxime or virucidal* or virucide* or "virus 
repressor*" or virustatic* or xanthogenate or "xenazoic acid" or zanamivir or 
Zanamivir or zinviroxime).mp. 
 4 or 5 or 6 1210019 
 exp Interferons/ 453948 
 exp interferon/ 453948 
0 
("cl 884" or cl884 or ifn or interferon* or interferone* or interferonogen* or 
interferron* or "interleukin 28A" or "interleukin 29" or "interleukin 6" or leif or 
peginterferon* or peginterferone* or peginterferonogen* or peginterferron*).mp. 
629323 
1 8 or 9 or 10 629423 
2 exp Carcinoma, Hepatocellular/ 142803 
3 exp liver cell carcinoma/ 142803 
4 exp Fibrosis/ 185872 
5 exp liver cirrhosis/ 157245 
6 exp Morbidity/ 612417 
7 exp Mortality/ 892082 
8 exp Death/ 531063 
9 exp Survival/ 616331 
0 mo.fs. 448163 
1 Virus Activation/ 7949 
2 exp virus reactivation/ 7579 
3 (((liver or hepatic) adj2 carcinoma*) or cirrhoses or cirrhosis or death or 4878731 
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decompensat* or "e AG" or eAG or fatal* or fibroses or fibrosis or flare* or HCC 
or hepatocarcinoma* or "hepatocellular carcinoma*" or hepatoma* or morbidity or 
mortality or myxofibroses or myxofibrosis or reactivat* or "s AG" or sAG or 
surviv*).mp. 
4 or/12-23 5422174 
5 3 and (7 or 11) and 24 19331 
6 exp evidence based medicine/ 722657 
7 exp meta analysis/ 134228 
8 exp Meta-Analysis as Topic/ 29609 
9 exp "systematic review"/ 79495 
0 exp Guideline/ or exp Practice Guideline/ 344743 
1 exp controlled study/ 4517923 
2 exp Randomized Controlled Trial/ 723728 
3 exp triple blind procedure/ 68 
4 exp Double-Blind Method/ 343004 
5 exp Single-Blind Method/ 51300 
6 exp latin square design/ 276 
7 exp comparative study/ 2460744 
8 exp intervention studies/ 29818 
9 exp Cross-Sectional Studies/ 307798 
0 exp Cross-Over Studies/ 101471 
1 exp Cohort Studies/ 1680879 
2 exp longitudinal study/ 1065173 
3 exp retrospective study/ 865208 
4 exp pros ective study/ 701582 
5 exp clinical trial/ 1729495 
6 clinical study/ 53696 
7 exp case-control studies/ 784997 
8 
((evidence adj based) or (meta adj analys*) or (systematic* adj3 review*) or 
guideline* or (control* adj2 study) or (control* adj2 trial) or (randomized adj2 
study) or (randomized adj2 trial) or (randomised adj2 study) or (randomised adj2 
trial) or (doubl* adj blind*) or (doubl* adj mask*) or (singl* adj blind*) or (singl* 
adj mask*) or (tripl* adj blind*) or (tripl* adj mask*) or (trebl* adj blind*) or 
(trebl* adj mask*) or "latin square" or placebo* or multivariate or "comparative 
study" or "comparative survey" or "comparative analysis" or (intervention* adj2 
study) or (intervention* adj2 trial) or "cross-sectional study" or "cross-sectional 
analys*" or "cross- sectional survey*" or "cross-sectional design*" or crossover or 
"cross-over" or "cohort study" or "cohort survey" or "cohort analysis" or 
"longitudinal study" or "longitudinal survey" or "longitudinal analysis" or 
"retrospective study" or "retrospective survey" or "retrospective analysis" or 
"prospective study" or "prospective survey" or "prospective analysis" or 
13490340 
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"concurrent study" or "concurrent survey" or "concurrent analysis" or "clinical 
study" or "clinical trial" or "case control study" or "case base study" or "case 
referrent study" or "case referent study" or "case compeer study" or "case 
comparison study" or cohort* or ((study or trial or random* or control*) and 
compar*)).mp. 
9 or/26-48 14249133 
0 25 and 49 10972 
1 from 25 keep 13107-18830 5724 
2 
limit 51 to (clinical trial, all or clinical trial, phase i or clinical trial, phase ii or 
clinical trial, phase iii or clinical trial, phase iv or clinical trial or comparative study 
or controlled clinical trial or guideline or meta analysis or multicenter study or 
practice guideline or pragmatic clinical trial or randomized controlled trial or 
systematic reviews) [Limit not valid in Embase,CCTR,CDSR; records were 
retained] 
1113 
3 50 or 52 10981 
4 
limit 53 to (book or book series or editorial or erratum or letter or note or addresses 
or autobiography or bibliography or biography or comment or dictionary or 
directory or interactive tutorial or interview or lectures or legal cases or legislation 
or news or newspaper article or overall or patient education handout or periodical 
index or portraits or published erratum or video-audio media or webcasts) [Limit 
not valid in Embase,Ovid MEDLINE(R),Ovid MEDLINE(R) In-
Process,CCTR,CDSR; records were retained] 
470 
5 53 not 54 10511 
6 from 25 keep 18831-19331 501 
7 55 or 56 10673 
8 
limit 57 to ("all adult (19 plus years)" or "young adult (19 to 24 years)" or "adult 
(19 to 44 years)" or "young adult and adult (19- 24 and 19-44)" or "middle age (45 
to 64 years)" or "middle aged (45 plus years)" or "all aged (65 and over)" or "aged 
(80 and over)") [Limit not valid in Embase,CCTR,CDSR; records were retained]  
9801 
9 
limit 58 to (adult <18 to 64 years> or aged <65+ years>) [Limit not valid in Ovid 
MEDLINE(R),Ovid MEDLINE(R) In-Process,CCTR,CDSR; records were 
retained] 
5259 
0 57 and (adult or adults or "middle age" or "middle aged").mp. 5349 
1 59 or 60 5510 
2 61 and chronic*.mp. 3604 
3 62 not (exp animals/ not exp humans/) 3519 
4 from 62 keep 3522-3604 83 
5 63 or 64 3602 
6 remove duplicates from 65 2441 
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1 TITLE-ABS-KEY("hepatitis B" or "serum hepatitis" or "hippie hepatitis" or "injection hepatitis" 
or "hepatitis type B") 
2 TITLE-ABS-KEY("1-Deoxynojirimycin" OR absouline OR "abt 333" OR "abt 450" OR 
Acetylcysteine OR aciclovir OR "acyclouridine derivative" OR Acyclovir OR "adenine xyloside" 
OR "adenosine dialdehyde" OR afovirsen OR "al 721" OR alamifovir OR alisporivir OR "aln rsv 
01" OR "alvircept sudotox" OR amantadine OR amenamevir OR amidapsone OR amitivir OR 
"ammonium trichloro dioxyethylene o o tellurate" OR amsacrine OR "ana 975" OR "anti viral 
agent" OR AntiRetroviral* OR "Anti-Retroviral*" OR antiretrovirus OR antiviral* OR "anti-
viral*" OR Aphidicolin OR arasangivamycin OR arbidol OR arildone OR astodrimer OR 
asunaprevir OR avarol OR avarone OR avridine OR "azd 7295" OR balapiravir OR 
bavituximab OR "behenyl alcohol" OR benzimidavir OR besifovir OR boceprevir OR 
bonaphthone OR "Brefeldin A" OR brincidofovir OR Bromodeoxyuridine OR bropirimine OR 
buciclovir OR carbocyclic OR carbodine OR carrageenan OR cidofovir OR ciluprevir OR 
clevudine OR "cpg 10101" OR crofelemer OR cyclaradine OR "cyclosporin A" OR cytarabine 
OR daclatasvir OR damavaricin OR danoprevir OR dasabuvir OR deitiphorin OR deleobuvir 
OR denotivir OR deoxyaristeromycin OR Deoxyglucose OR deoxypenciclovir OR 
deoxyribavirin OR desciclovir OR detiviciclovir OR "didemnin A" OR "didemnin B" OR 
Dideoxyadenosine OR Dideoxynucleoside* OR disoxaril OR "distamycin 5" OR "distamycin A" 
OR Ditiocarb OR droxinavir OR edoxudine OR elbasvir OR "enisamium iodide" OR enviroxime 
OR epetirimod OR eudistomin OR exbivirumab OR faldaprevir OR famciclovir OR favipiravir 
OR felvizumab OR fiacitabine OR fialuridine OR filibuvir OR Filipin OR florenal OR 
"flucytosine arabinoside" OR fomivirsen OR foravirumab OR fosarilate OR foscarnet OR 
fosdevirine OR fucoidin OR "gamma venin" OR ganciclovir OR "gene expression modulator" 
OR grazoprevir OR "gs 9256" OR "guanine 7 oxide" OR hypericin OR "hypoxanthine 
arabinoside" OR idoxuridine OR "idoxuridine derivative" OR "idx 184" OR imexon OR 
imiquimod OR "Inosine Pranobex" OR iododeoxycytidine OR ipilimumab OR isatoribine OR 
"isis 13312" OR "isis 14803" OR laninamivir OR larifan OR ledipasvir OR letermovir OR 
levovirin OR lexithromycin OR libivirumab OR litomeglovir OR lomibuvir OR mericitabine OR 
merimepodib OR Methisazone OR methisoprinol OR methylcytidine OR metisazone OR 
miravirsen OR moroxydine OR motavizumab OR "mycophenolic acid" OR "Myxovirus 
resistance protein" OR "n bromoacetyldistamycin A" OR narlaprevir OR neceprevir OR 
"neominophagen C" OR nesbuvir OR netivudine OR netropsin OR nivocasan OR omaciclovir 
OR ombitasvir OR oseltamivir OR palivizumab OR penciclovir OR "penciclovir triphosphate" 
OR peramivir OR "phosphonoacetic acid" OR "Phosphonoacetic Acid" OR pirazofurin OR 
pirodavir OR pleconaril OR pocapavir OR "pokeweed antivirus protein" OR "Poly A-U" OR 
"Poly I-C" OR pritelivir OR pseudohypericin OR "pyran copolymer" OR "Pyran Copolymer" OR 
radavirsen OR rafivirumab OR "recombinant intercellular adhesion molecule 1" OR 
regavirumab OR resiquimod OR ribavirin OR "ribavirin derivative" OR rifabutin OR 
rimantadine OR rintatolimod OR riodoxol OR rociclovir OR rupintrivir OR samatasvir OR 
sangivamycin OR "sangivamycin derivative" OR "scopadulcic acid B" OR setrobuvir OR 
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sevirumab OR simeprevir OR sofosbuvir OR sorivudine OR sovaprevir OR streptovaricin OR 
Streptovaricin OR streptovirudin OR suramin OR suvizumab OR synadenol OR synguanol OR 
taribavirin OR tebrofen OR tecovirimat OR tegobuvir OR telaprevir OR telbivudine OR 
"Tenuazonic Acid" OR "thiarubrine A" OR "thiophene A" OR "thymine arabinoside" OR 
tilorone OR Tilorone OR "tilorone derivative" OR tiviciclovir OR tomeglovir OR torcitabine OR 
trifluridine OR tromantadine OR tunicamycin OR tuvirumab OR umifenovir OR "uracil 
arabinoside" OR valaciclovir OR valganciclovir OR valomaciclovir OR valopicitabine OR 
valtorcitabine OR vaniprevir OR vapendavir OR vedroprevir OR vidarabine OR Vidarabine OR 
viracine OR "viral inhibitor*" OR virantmycin OR virostatic* OR viroxime OR virucidal* OR 
virucide* OR "virus repressor*" OR virustatic* OR xanthogenate OR "xenazoic acid" OR 
zanamivir OR Zanamivir OR zinviroxime) 
3 TITLE-ABS-KEY("cl 884" OR cl884 OR ifn OR interferon* OR interferone* OR interferonogen* 
OR interferron* OR "interleukin 28A" OR "interleukin 29" OR "interleukin 6" OR leif OR 
peginterferon* OR peginterferone* OR peginterferonogen* OR peginterferron*) 
4 TITLE-ABS-KEY(((liver or hepatic) W/2 carcinoma*) OR cirrhoses OR cirrhosis OR death OR 
decompensat* OR "e AG" OR eAG OR fatal* OR fibroses OR fibrosis OR flare* OR HCC OR 
hepatocarcinoma* OR "hepatocellular carcinoma*" OR hepatoma* OR morbidity OR 
mortality OR myxofibroses OR myxofibrosis OR reactivat* OR "s AG" OR sAG OR surviv*) 
5 TITLE-ABS-KEY(chronic*) 
6 TITLE-ABS-KEY((evidence W/1 based) or (meta W/1 analys*) or (systematic* W/3 review*) 
or guideline* or (control* W/2 study) or (control* W/2 trial) or (randomized W/2 study) or 
(randomized W/2 trial) or (randomised W/2 study) or (randomised W/2 trial) or (doubl* 
W/1 blind*) or (doubl* W/1 mask*) or (singl* W/1 blind*) or (singl* W/1 mask*) or (tripl* 
W/1 blind*) or (tripl* W/1 mask*) or (trebl* W/1 blind*) or (trebl* W/1 mask*) or "latin 
square" or placebo* or multivariate or "comparative study" or "comparative survey" or 
"comparative analysis" or (intervention* W/2 study) or (intervention* W/2 trial) or "cross-
sectional study" or "cross-sectional analys*" or "cross- sectional survey*" or "cross-sectional 
design*" or crossover or "cross-over" or "cohort study" or "cohort survey" or "cohort 
analysis" or "longitudinal study" or "longitudinal survey" or "longitudinal analysis" or 
"retrospective study" or "retrospective survey" or "retrospective analysis" or "prospective 
study" or "prospective survey" or "prospective analysis" or "concurrent study" or 
"concurrent survey" or "concurrent analysis" or "clinical study" or "clinical trial" or "case 
control study" or "case base study" or "case referrent study" or "case referent study" or 
"case compeer study" or "case comparison study" or cohort* or ((study or trial or random* 
or control*) and compar*)) 
7 TITLE-ABS-KEY(adult or adults or "middle age" or "middle aged") 
8 1 and (2 or 3) and 4 and 5 and 6 and 7 
9 DOCTYPE(le) OR DOCTYPE(ed) OR DOCTYPE(bk) OR DOCTYPE(er) OR DOCTYPE(no) OR 
DOCTYPE(sh) 
10 8 and not 9 
11 PMID(0*) OR PMID(1*) OR PMID(2*) OR PMID(3*) OR PMID(4*) OR PMID(5*) OR PMID(6*) 
OR PMID(7*) OR PMID(8*) OR PMID(9*) 
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0 and not 11 
Page 51 of 61
Hepatology
Hepatology












Supplemental File 3: 
Indirect and non-comparative evidence 
 
PICO3: Can antiviral therapy, specifically nucleos(t)ide analogues be stopped in HBeAg-positive 
persons who achieved HBeAg seroconversion?  
 
An extensive review by the Evidence Practice Center at Mayo Clinic found only 2 studies comparing 
HBeAg-positive persons receiving nucleos(t)ide analogue therapy for chronic hepatitis B who stopped 
treatment after achieving HBeAg seroconversion to those who did not. There are other studies in the 
published literature on this topic. These studies focused on describing viral relapse, hepatitis flares and 
HBeAg seroreversion but did not report on clinical outcomes. They also did not have a comparison group 
that continued treatment. Some studies did examine the durability of response in relation to the duration 
of consolidation therapy, i.e. duration of continued treatment after achieving HBeAg seroconversion.  
One retrospective study in Korea included 178 patients who received lamivudine and achieved HBeAg 
seroconversion (1). Cumulative relapse rate 5 years after stopping treatment was 8.7% vs. 61.9% for 
patients who had <12 vs ≥12 months consolidation therapy (p<0.001). Independent predictors of relapse 
were age >40 years and duration of consolidation therapy <12 months.  
Another retrospective study included 88 Asian patients who achieved HBeAg seroconversion on various 
nucleos(t)ide analogues, 49 continued treatment and all maintained undetectable HBV DNA. Of the 39 
who stopped treatment, 35 had viral relapse, 15 had biochemical relapse (ALT >2 times upper limit of 
normal (x ULN)), and 3 had HBeAg seroreversion (2). Risk of viral relapse was not related to the 
duration of consolidation therapy.  
A recent retrospective study from 3 Asian centers included 101 patients who stopped lamivudine 
treatment after achieving HBeAg seroconversion found that response was maintained in 25.6%, 39.0%, 
and 71.4% of patients who had consolidation therapy for <12, 12-18 and >18 months, respectively (3).  
Despite these discrepant findings, duration of consolidation therapy is the most consistent predictor of 
durable response in patients who stopped nucleos(t)ide analogue therapy after achieving HBeAg 
seroconversion followed by age of patients (1, 3-8). Collectively, these data indicate that viral relapse is 
common in HBeAg-positive patients who stopped nucleos(t)ide analogue therapy after achieving HBeAg 
seroconversion. A longer duration of consolidation therapy (>12 months) decreases but does not eliminate 
the risk of relapse.   
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 PICO 4: Can antiviral therapy, specifically nucleos(t)ide analogues be stopped in HBeAg-negative 
persons? What is the impact on cirrhosis, hepatic decompensation, HCC, relapse (viral and clinical) 
and HBsAg loss in patients who stopped versus those who continued therapy?  
 
An extensive review by the Evidence Practice Center at Mayo Clinic failed to find any RCT or cohort 
studies examining the outcomes of cirrhosis, hepatic decompensation, HCC, relapse (viral and clinical), 
and HBsAg loss comparing HBeAg-negative persons receiving nucleos(t)ide analogue therapy for 
chronic hepatitis B who stopped treatment compared to those who did not. We reviewed the literature 
looking specifically for titles of articles describing case series of HBeAg-negative persons receiving 
nucleos(t)ide analogues who stopped treatment. We found 6 retrospective studies on this topic that 
provide some guidance on this clinically important question.  
Of note, the Asian Pacific Association for the Study of the Liver (APASL) 2012 guidelines stated that 
treatment may be discontinued in HBeAg-negative patients who completed at least 2 years of 
nucleos(t)ide analogue treatment and have undetectable HBV DNA on at least 3 occasions that are at least 
6 months apart (9). This recommendation was based on results of a study of 27 HBeAg-negative patients 
who stopped lamivudine after 2 years of treatment and had three consecutive undetectable HBV DNA ≥3 
months apart in year 2 of treatment. In that study, the cumulative probability of viral relapse (defined as 
reappearance of HBV DNA by PCR) at 6, 12, and 18 months was 30%, 50%, and 50% respectively; and 
of clinical relapse (defined as HBV DNA >30,000 IU/ml and ALT >1.5x ULN) 12%, 18% and 30%, 
respectively (10). The APASL recommendations were mostly driven by financial considerations because 
coverage of HBV medications by the government in Asian countries, particularly for those with no 
cirrhosis, is often limited to 2-3 years.  
A subsequent study in China of 61 HBeAg-negative patients who received lamivudine for a median of 27 
(24-66) months and who had undetectable HBV DNA and normal ALT for 18 months found that 
cumulative rates of viral relapse (defined as HBV DNA >2,000 IU/ml on 2 consecutive samples at least 1 
week part) at 1, 2, 3, 4 and 5 years were 43.6%, 49.7%, 52.1%, 56.1%, and 56.1%, respectively (11).  
In the third study from Greece, 33 HBeAg-negative non-cirrhotic patients with undetectable HBV DNA 
and normal ALT after 4-5 years of adefovir treatment stopped therapy and were followed for a median of 
69 (range 67-72) months (12). All had virologic relapse defined as increase in HBV DNA to >2000 
IU/ml. In most patients, peak HBV DNA occurred during the first 2 months after treatment was stopped. 
25 (76%) patients had biochemical relapse defined as ALT >1.2x ULN. During the follow-up period, 18 
patients (55%) who had discontinued antiviral therapy achieved sustained virologic response (HBV DNA 
<2000 IU/ml and persistently normal ALT). Among these, 13 (72%) cleared HBsAg. Multivariate 
analysis found that higher pretreatment and end of treatment levels of ALT, no previous treatment with 
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interferon, and lower levels of HBsAg at the end of treatment were significantly associated with HBsAg 
clearance.  
A fourth study conducted in Taiwan tested the validity of the APASL recommendations. In this study, 95 
HBeAg-negative patients who met APASL criteria for stopping nucleos(t)ide analogue treatment and had 
at least 1 year post-treatment follow-up were studied (13). 39 (41.1%) of the patients had clinical or 
histological evidence of cirrhosis. Median duration of entecavir treatment prior to stopping therapy was 
721 (range 395-1762) days. Within 1 year after stopping treatment, 43 (45.3%) patients experienced 
clinical relapse defined as ALT >2x ULN and HBV DNA >2000 IU/ml. Of the 39 patients with cirrhosis, 
17 (43.6%) had clinical relapse and 1 (2.6%) had decompensation. Median duration to clinical relapse 
was 230 (range 79-368) days with74.4% clinical relapses occurring beyond 6 months after stopping 
treatment. Logistic regression analysis showed that baseline HBV DNA >200,000 IU/ml was the only 
predictor of clinical relapse.   
The fifth study also conducted in Taiwan included 263 consecutive patients (94 with cirrhosis) who 
stopped lamivudine after recovering from a flare of hepatitis with hepatic decompensation (14). 147 
patients (64 cirrhosis and 83 non-cirrhotic) were HBeAg-negative at the start of treatment. Mean duration 
of lamivudine was 12.1 ± 8.6 months. 139 patients resumed treatment. Within the first year of stopping 
treatment, 29.9% of patients had clinical relapse, 16.2% had hepatitis flares, and 8.2% had hepatic 
decompensation. Three patients with cirrhosis died of hepatic decompensation. Multivariate analysis 
showed that men were more likely to have hepatic decompensation.   
The sixth study, conducted in Korea, presented at the AASLD Annual Meeting in 2014 and published in 
abstract form found that 54% of HBeAg-negative patients who met APASL criteria for stopping antiviral 
therapy relapsed within 1 year of stopping treatment (15).  
Collectively, these studies showed that cessation of nucleos(t)ide therapy is possible in some HBeAg-
negative patients who have completed 2-5 years of nucleos(t)ide analogue therapy and have persistently 
undetectable HBV DNA. Clinical factors associated with a successful outcome after stopping antiviral 
therapy have not been identified. Viral relapse is common but not all patients experience clinical relapse 
necessitating re-treatment. However, hepatic decompensation and death can occur and this risk appears to 
be higher in those with cirrhosis at the start of treatment.  
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PICO #6: Adding a second antiviral agent compared to continuing monotherapy (entecavir or 
tenofovir) in patients with chronic HBV infection and persistent viremia? 
 
For add-on therapy in patients who failed to achieve viral suppression with either tenofovir or entecavir 
monotherapy, we did not identify any RCT comparing adding a second antiviral agent versus continuing 
tenofovir or entecavir monotherapy. We did identify 1 RCT comparing de novo combination of entecavir 
and tenofovir vs entecavir monotherapy. Clinical outcomes were not reported. De novo combination 
therapy did not result in higher rates of intermediate responses except in the subset of patients with high 
viremia (>108 IU/ml) where a higher proportion (79% vs 62%) of patients had HBV DNA suppression to 
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PICO 7: Hepatitis B and compensated cirrhosis with low level viremia (<2,000 IU/ml) 
An extensive review by the Evidence Practice Center at Mayo Clinic failed to find any RCT or cohort 
studies examining the outcomes of liver related death, HCC and hepatic decompensation comparing 
persons who received antiviral therapy for HBV compensated cirrhosis and low level viremia (<2,000 
IU/ml) compared to those who did not. We reviewed the literature looking specifically for titles of articles 
describing case series on persons with cirrhosis who had low level viremia and received antiviral therapy. 
No specific titles or abstracts were found. One retrospective study of 385 treatment-naïve patients with 
HBV-related compensated cirrhosis and HBV DNA <2,000 IU/ml found that 5-year cumulative HCC 
incidence rate was 2.2%, 8.0% and 14.0% for patients with baseline undetectable HBV DNA (<12 
IU/ml), detectable HBV DNA <2,000 IU/ml and normal ALT, and detectable HBV DNA <2,000 IU/ml 
and elevated ALT, respectively (17). During follow up, 77 patients started antiviral therapy. In patients 
who did not receive antiviral therapy, the 5-year cumulative HCC incidence rates were 13.3%, 8.8% and 
1.4% for patients who experienced HBV DNA increase, patients who maintained detectable HBV DNA 
<2,000 IU/ml, and patients who maintained undetectable HBV DNA, respectively. In patients who started 
antiviral therapy, the 5-year cumulative HCC incidence rate was 5.9% and longer duration of antiviral 
therapy and longer duration of complete virological response were associated with lower HCC risk. These 
data suggest that antiviral therapy may decrease the risk of HCC in patients with compensated cirrhosis 
and low level viremia but characteristics of patients who did and those who did not start antiviral therapy 
were different. In addition, in many patients who received treatment, HBV DNA levels were >2,000 
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Supplemental Table 4: Summary of evidence:  
Intervention 










Question 1: Effectiveness of antiviral therapy in patients with immune active chronic HBV infection: 
Any Antiviral vs None 
(28 months for RCTs, 60 months 
for observational studies) 




(0.16 to 1.29) 












(0.29 to 0.68) 





































(0.38 to 0.78) 
HBsAg loss or 















(0.38 to 0.61) 












(0.22 to 0.89) 
Compensated 
Cirrhosis 
IFN vs. None 
 




(0.33 to 1.53) 












(0.33 to 1.48) 
Lamivudine vs.  
None 
 









(0.35 to 0.58) 












(0.25 to 0.46) 
Entecavir vs. 
None 












(0.13 to 0.53) 
Decompensated Lamivudine vs. All-cause mortality (2 observational ⨁◯◯◯1 RR 0.46 




















































































(0.27 to 0.99) 




(0.64 to 0.81) 
Lamivudine vs.  
None 
 




(0.68 to 0.88) 
Entecavir vs. 






(0.55 to 0.79) 
Tenofovir vs. 




(0.27 to 0.99) 
Telbivudine vs. 












































(0.26 to 3.97) 
All-cause mortality 












(0.45 to 1.15) 
Liver transplant 




(0.96 to 11.58) 














































































(0.51 to 1.74) 
All-cause mortality 

















(0.72 to 2.39) 









































































Question 2. Effectiveness of antiviral therapy in patients with immune-tolerant chronic HBV infection: 
Peg IFN + Adefovir vs. Control 
 












(2.62 to 666.87) 








(1.1 to 1.8) 
















Question 3: Discontinuing vs. continuing antiviral therapy in HBeAg positive patients who seroconverted from HBeAg to anti-
HBe: 
Stopped vs. Continued therapy 
 









(0.36 to 112.47) 
Question 5. Safety of entecavir compared to tenofovir: 
Tenofovir vs. Entecavir 
Increase in 

















(0.06 to 35.4) 
Increase in 
Creatinine of ≥ 0.5 
mg/dl from 
baseline 





(0.07 to 9.979) 







(0.65 to 1.32) 
































(0.12 to 7.59) 
Footnotes: 




eGFR: estimated glomerular filtration rate 
** Chou R, Dana T, Bougatsos C, Blazina I, Khangura J, Zakher B. Screening for hepatitis B virus infection in adolescents and adults: a 
systematic review to update the U.S. Preventive Services Task Force recommendation. Annals of Internal Medicine 2014;161:31-45. 
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